Biosimilar User Fee Forecast: Unchanged Or Lower In FY 2019, US FDA Says

Absence of any fee increases reflects growing numbers of both approved biosimilars and products under development, as well as agency’s commitment to start spending down some of the carryover balance from prior years’ fee collections.

PS1807_Fees_336450779_1200.jpg

Biosimilar product developers will find good news in the US FDA user fee rates for the coming fiscal year, with product development fees declining and the levies for applications and approved products remaining unchanged.

The absence of any fee increases in fiscal year 2019 reflects a combination of factors, including growing numbers of both...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Biosimilars & Generics